Actor portrayals.
Flexible options for administration either orally or via PEG/NG tube.1
5 mL dose administered in minutes, not hours
Portable—patients can take it at home or on the goa (see footnote)
28-day treatment cycles
(see dosing schedule below)
RADICAVA ORS® contains sorbitol, an ingredient with a mildly sweet taste1,2
No water or reconstitution needed
(shaking required)
Patient to store at room temperature between 20°C-25°C (68°F-77°F)a (see footnote)
RADICAVA ORS® should be administered using the provided 5 mL syringe. A household teaspoon is not an adequate measuring device.
Not actual size.
Not actual size.
Patients may be switched from 60 mg RADICAVA® intravenous infusion to 105 mg (5 mL) RADICAVA ORS® using the same dosing frequency.1
Watch a brief video that explains how patients take RADICAVA ORS® oral treatment.
FDA-approved and indicated for the treatment of ALS
May be received with riluzole
No known drug interactionsb (see footnote)
(see full Prescribing Information)
Use the Benefit Investigation and Submission Form (BIF) to start patients on treatment.
RADICAVA® is an intravenous (IV) medication for the treatment of ALS. The recommended dosage is 60 mg administered over a 60-minute period.1 RADICAVA® IV may be administered at an infusion center, a doctor's office, a hospital, or at home. Patients should consult their healthcare provider (HCP) and insurance plan to determine which option is right for them.
IV infusion (60 mg)1
Two 30 mg bags
60 minutes to receive full dose1
Watch a brief video that explains how to administer and store RADICAVA® IV. See the full Prescribing Information for complete dosage and administration information.
Ready to prescribe RADICAVA ORS® or RADICAVA® IV?
Follow these instructions to help prevent damage to the stopper and avoid leakage of medication. You can also download these instructions.
Handle the bag gently. Hold the bag with the rubber stopper facing upward. If the bag is already hanging, remove it from the IV pole. Align the spike to the center of the stopper without twisting. DO NOT spike upward. It is important NOT to insert the spike at an angle.
Very gently and carefully insert the spike straight into the center of the stopper. It is important not to twist the spike when inserting it into the IV bag. Be sure to only spike once.
During insertion:
Doing so may damage the stopper and cause medication leakage.
NEVER INFUSE A BAG IF THE SPIKE HAS BEEN IMPROPERLY INSERTED INTO THE RUBBER STOPPER, CAUSING MEDICATION LEAKAGE.
RADICAVA® IV is an ongoing treatment for ALS. For the first cycle, RADICAVA® IV is infused for 14 days, followed by a 14-day drug-free period. Subsequent cycles are infused for 10 days within a 14-day period, followed by a 14-day drug-free period.1
RADICAVA® IV may be administered via a central or peripheral IV device. To learn more, you can download information about these modes of infusion.
Searching for an infusion site of care? Use our ALS Care Locator.
aIn the pharmacy, store RADICAVA ORS® refrigerated between 2°C-8°C (36°F-46°F) and protect from light. Do not freeze. Store upright. Patients should store RADICAVA ORS® upright at room temperature between 20°C-25°C (68°F-77°F) and protect from light. Discard 15 days after opening bottle or, if unopened, 30 days from date of shipment indicated on the carton pharmacy label.1 Return to content
bBased on in vitro drug interaction studies. Return to content
PEG=percutaneous endoscopic gastrostomy.
References: 1. RADICAVA and RADICAVA ORS Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2022. 2. National Center for Biotechnology Information. PubChem compound summary for CID 5780, sorbitol. Accessed November 8, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/Sorbitol.
RADICAVA (edaravone) and RADICAVA ORS (edaravone) are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred with RADICAVA.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA-treated patients were contusion (15%), gait disturbance (13%), and headache (10%). In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA and RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information.
RADICAVA (edaravone) and RADICAVA ORS (edaravone) are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred with RADICAVA.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA-treated patients were contusion (15%), gait disturbance (13%), and headache (10%). In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA and RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information.
RADICAVA, RADICAVA ORS, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks, and the RADICAVA ORS logo is a trademark, of Mitsubishi Tanabe Pharma Corporation.
JourneyMate Support Program is a trademark of Mitsubishi Tanabe Pharma America, Inc.
All other company names, product names, trade/service marks or other trade names are the property of their respective owners.
For US Healthcare Professionals Only.
© 2023 Mitsubishi Tanabe Pharma America, Inc. All rights reserved. CP-RC-US-1967 07/23
You are leaving this website, hosted by Mitsubishi Tanabe Pharma America.
This link may take you to a website to which our Privacy Policy does not apply.
Mitsubishi Tanabe Pharma America does not control the content of third-party sites.
